Keeping veterinary medicines safe after they reach the market is not simply a regulatory expectation—it is an ongoing responsibility. Under EU veterinary pharmacovigilance legislation, marketing authorisation holders (MAHs) must continuously monitor the safety of their products, identify emerging risks, and take appropriate action whenever new safety concerns arise. At the centre of this process is veterinary signal detection, which enables companies to identify previously unknown adverse reactions or changes in the benefit-risk balance before they become significant safety issues.
For many companies, however, maintaining an effective veterinary signal detection process is becoming increasingly challenging. It requires experienced pharmacovigilance specialists, robust quality systems, scientific evaluation, documented procedures, and continuous surveillance of multiple safety data sources. Limited internal resources, growing product portfolios, and evolving regulatory requirements often make it difficult to perform these activities consistently while remaining inspection-ready.
As a result, many organisations search online for “which firms handle signal detection for veterinary drugs” to identify experienced partners that can support or fully manage this critical pharmacovigilance function. However, not all providers offer the same level of veterinary expertise, regulatory knowledge, or strategic support. Choosing the right partner can make the difference between simply meeting regulatory obligations and building a proactive, high-quality veterinary pharmacovigilance system that protects animal health, supports compliance, and reduces operational burden.
Which firms handle signal detection for veterinary drugs?
Companies looking for veterinary signal detection support can choose from several types of organisations. These typically include specialist pharmacovigilance service providers, contract research organisations (CROs), regulatory consulting companies, and full-service regulatory partners offering integrated pharmacovigilance support. Many of these organisations also provide veterinary pharmacovigilance outsourcing services, allowing marketing authorisation holders to outsource individual pharmacovigilance activities or their entire veterinary pharmacovigilance system while retaining overall regulatory responsibility.
While each type of organisation may provide veterinary signal detection services, the scope of expertise can vary significantly. Some providers focus primarily on adverse event processing or statistical signal detection, whereas others manage the complete signal management process, including signal validation, scientific assessment, benefit-risk evaluation, regulatory recommendations, documentation, and ongoing compliance with Regulation (EU) 2019/6 and the EMA Veterinary Good Pharmacovigilance Practices (VGVP). Companies seeking comprehensive veterinary pharmacovigilance outsourcing should therefore look for providers capable of supporting the full pharmacovigilance lifecycle rather than isolated activities.
When deciding which firms handle signal detection for veterinary drugs, companies should evaluate not only the services offered but also the provider’s veterinary pharmacovigilance expertise, quality management systems, regulatory knowledge, and ability to support long-term compliance. Selecting the right partner for veterinary pharmacovigilance outsourcing helps ensure consistent product safety monitoring, inspection readiness, and efficient management of pharmacovigilance obligations while reducing both operational and regulatory risk.
What must companies do to comply with veterinary signal detection requirements?
To comply with European veterinary pharmacovigilance legislation, marketing authorisation holders (MAHs) must establish and maintain a documented veterinary signal detection process throughout the entire lifecycle of every authorised veterinary medicinal product. Under Regulation (EU) 2019/6 and the EMA Veterinary Good Pharmacovigilance Practices (VGVP), companies are responsible for continuously monitoring all relevant pharmacovigilance data, identifying potential safety signals, scientifically evaluating their significance, and taking appropriate regulatory action whenever the benefit-risk balance may have changed. Effective signal detection in veterinary pharmacovigilance is therefore a fundamental component of every compliant veterinary pharmacovigilance system.
An effective veterinary signal detection programme goes far beyond reviewing adverse event reports. Companies should collect and evaluate information from multiple data sources, including spontaneous adverse event reports, scientific literature, clinical studies, EudraVigilance Veterinary, sales data, and any other relevant pharmacovigilance information that may contribute to signal identification. Potential signals must then be prioritised, validated, assessed using scientific and medical expertise, documented, and monitored until an appropriate conclusion has been reached. Where a validated signal indicates a new risk or a change in the benefit-risk balance, companies are required to notify the competent authorities within the applicable regulatory timelines and implement any necessary risk minimisation measures.
Beyond the scientific assessment itself, organisations should also implement robust governance procedures, standard operating procedures (SOPs), quality management systems, clearly defined responsibilities, and complete documentation demonstrating that every signal has been managed in accordance with regulatory expectations. Because veterinary signal management is an ongoing process rather than a one-time activity, many companies choose to strengthen their internal capabilities or outsource these activities to experienced veterinary pharmacovigilance specialists who can ensure both regulatory compliance and inspection readiness.
Why choose Billev Pharma East for veterinary signal detection?
Maintaining a compliant veterinary signal detection process requires more than reviewing adverse event reports. It demands scientific expertise, veterinary pharmacovigilance knowledge, regulatory understanding, robust quality systems, and the resources to continuously monitor, assess, document, and manage safety signals throughout the product lifecycle. For many marketing authorisation holders, building and maintaining these capabilities internally can be resource-intensive and difficult to scale.
At Billev Pharma East, we act as an extension of your pharmacovigilance team, providing expert support across the entire veterinary signal management process. Our specialists combine extensive experience in veterinary pharmacovigilance, regulatory affairs, medical evaluation, and quality management to help companies meet their regulatory obligations with confidence. We work with veterinary medicinal products throughout Europe and support clients in maintaining compliant pharmacovigilance systems that align with Regulation (EU) 2019/6 and the EMA Veterinary Good Pharmacovigilance Practices (VGVP).
Our multidisciplinary team combines expertise in veterinary pharmacovigilance, regulatory affairs, medical writing, quality management systems, and European regulatory procedures. This allows us to support veterinary medicinal products throughout their entire lifecycle—from market authorisation and routine pharmacovigilance activities to signal management, inspections, and ongoing regulatory compliance.
Unlike providers that offer signal detection as a standalone activity, we deliver a fully integrated veterinary pharmacovigilance solution. Alongside veterinary signal detection, we support adverse event case management, literature monitoring, veterinary QPPV services, Pharmacovigilance System Master File (PSMF) maintenance, annual statement preparation, signal evaluation reporting, SOP development, quality management systems, audits, inspection readiness, medical writing, and regulatory consulting. This integrated approach ensures that every safety signal is evaluated within the broader context of your pharmacovigilance system, reducing regulatory risk while improving operational efficiency.
Whether you need to outsource your entire veterinary signal detection process or strengthen your existing pharmacovigilance capabilities, Billev Pharma East provides a flexible, scalable solution tailored to your organisation. Our goal is simple: to help you identify emerging safety risks early, maintain continuous regulatory compliance, and protect both animal health and your products throughout their lifecycle. When companies search “which firms handle signal detection for veterinary drugs,” they are ultimately looking for a trusted long-term partner—and that is exactly what we strive to be.
What should companies consider when selecting a veterinary signal detection partner?
When evaluating which firms handle signal detection for veterinary drugs, companies should look beyond whether a provider offers signal detection as a standalone service. The real question is whether the organisation has the scientific expertise, regulatory knowledge, and operational capabilities to manage the entire signal management process in accordance with European requirements. Under the EMA Veterinary Good Pharmacovigilance Practices (VGVP), signal management is a structured process that includes signal detection, prioritisation, validation, assessment, documentation, and, where necessary, regulatory action.
One of the most important considerations is veterinary-specific expertise. Signal detection is not simply a statistical exercise or a review of adverse event reports. It requires experienced veterinary pharmacovigilance professionals who understand veterinary medicinal products, can interpret data from multiple sources—including EudraVigilance Veterinary, scientific literature, and spontaneous adverse event reports—and perform scientifically sound benefit-risk assessments. Providers should also operate within a robust quality management system supported by documented SOPs, clearly defined governance, and inspection-ready documentation.
Companies should also consider whether a provider can support their long-term pharmacovigilance strategy rather than addressing individual signals in isolation. As product portfolios grow and regulatory expectations continue to evolve, organisations increasingly benefit from working with a partner that can integrate veterinary signal detection with the wider pharmacovigilance system, including case processing, literature monitoring, annual statement preparation, signal evaluation reporting, QPPV support, PSMF maintenance, regulatory consulting, and quality management. Choosing a provider with comprehensive veterinary pharmacovigilance expertise helps ensure consistent compliance, reduces operational burden, and strengthens product safety throughout the product lifecycle.
Benefits of outsourcing veterinary signal detection
Outsourcing veterinary signal detection allows companies to access experienced pharmacovigilance professionals without the need to build or expand internal specialist teams. This approach helps organisations maintain continuous compliance while reducing operational complexity and ensuring that signal management activities are performed according to current regulatory expectations.
Working with an experienced partner also provides access to established quality systems, documented procedures, inspection-ready documentation, and multidisciplinary expertise covering veterinary pharmacovigilance, regulatory affairs, and medical evaluation. As product portfolios expand and safety data volumes increase, outsourced signal detection offers the flexibility and scalability needed to support long-term pharmacovigilance activities while allowing internal teams to focus on strategic priorities.
For many marketing authorisation holders, outsourcing is no longer simply a resource-saving measure—it has become an effective way to strengthen product safety, improve regulatory compliance, and maintain a proactive veterinary pharmacovigilance system.
Strengthen your veterinary signal detection strategy with Billev Pharma East
An effective veterinary signal detection process is essential for protecting animal health, maintaining a favourable benefit-risk balance, and ensuring compliance with Regulation (EU) 2019/6 and the EMA Veterinary Good Pharmacovigilance Practices. However, achieving this requires much more than periodic safety reviews—it demands continuous monitoring, scientific expertise, robust quality systems, and a structured approach to signal management throughout the entire product lifecycle.
At Billev Pharma East, we help veterinary pharmaceutical companies transform these regulatory obligations into efficient, inspection-ready pharmacovigilance processes. Whether you need a trusted partner to fully outsource veterinary signal detection or additional expertise to strengthen your existing pharmacovigilance team, we provide tailored solutions that combine scientific excellence, regulatory expertise, and practical operational support.
If you are searching for which firms handle signal detection for veterinary drugs, choose a partner that delivers more than compliance. Partner with Billev Pharma East to build a proactive veterinary pharmacovigilance system that identifies emerging safety risks early, reduces regulatory burden, and supports the long-term success of your veterinary medicinal products. Contact our team to discuss how we can support your veterinary signal detection strategy.
Frequently asked questions
What is veterinary signal detection?
Veterinary signal detection is the continuous process of identifying new or changing safety information associated with veterinary medicinal products. It forms part of the broader signal management process described in the EMA Veterinary Good Pharmacovigilance Practices and helps marketing authorisation holders identify potential risks that may affect the benefit-risk balance of a product.
Is veterinary signal detection mandatory?
Yes. Under Regulation (EU) 2019/6, marketing authorisation holders must continuously monitor the safety of their veterinary medicinal products and maintain an effective veterinary signal detection process throughout the product lifecycle.
Can veterinary signal detection be outsourced?
Yes. Companies may outsource veterinary signal detection to experienced pharmacovigilance service providers or regulatory partners. However, regulatory responsibility always remains with the marketing authorisation holder, making it important to select a provider with appropriate veterinary pharmacovigilance expertise and robust quality systems.
Who is responsible for veterinary signal detection?
Although signal detection activities may be outsourced, the marketing authorisation holder remains legally responsible for ensuring that veterinary signal detection is performed in accordance with applicable regulatory requirements and that appropriate actions are taken when validated safety signals are identified.
Sources: 1 – European Medicines Agency. (2021). Guideline on veterinary good pharmacovigilance practices (VGVP) – Module: Signal Management, 2 – European Medicines Agency. (n.d.). Veterinary good pharmacovigilance practices (VGVP), 3 – European Medicines Agency. (n.d.). Signal management (veterinary medicines), 4 – European Medicines Agency. (2021). Guideline on veterinary good pharmacovigilance practices (VGVP) – Module: Pharmacovigilance systems, their quality management systems and pharmacovigilance system master files, 5 – European Parliament and the Council of the European Union. (2019). Regulation (EU) 2019/6 on veterinary medicinal products, 6 – European Medicines Agency. (n.d.). Pharmacovigilance system (veterinary medicines).
Image credits:
In-article images: Pexels
In-article images: Pexels
Hero image: Pexels